Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice

Panebianco, Concetta; Adamberg, Kaarel; Jaagura, Madis; Copetti, Massimiliano; Fontana, Andrea; Adamberg, Signe; Kolk, K W Van De; Vilu, Raivo; Andriulli, Angelo; Pazienza, Valerio

doi:10.1007/s00280-018-3549-0

Cited by 78 publications

(67 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For this reason we performed a metabolomics targeted analysis of mice serum. Beside the decreased level of inosine, xanthine and hypoxantine that we discussed in our previous work [12] we also observed a decreased level of the essential aminoacid methionine. Several studies showed that methionine restriction also inhibits aging-related disease processes in mice and inhibits colon carcinogenesis in rats [21] and in humans, methionine restriction could be achieved through a plant-based diet [22].…”

Section: Discussionsupporting

confidence: 80%

Inhibition of pyruvate dehydrogenase kinase influence microbiota and metabolomic profile in pancreatic cancer xenograft mice

Adamberg

Vilu

Pazienza³

2020

Preprint

Self Cite

View full text Add to dashboard Cite

Objective Despite recent advances in treatment options, pancreatic cancer remains the most deadly major cancer. Targeting metabolism represents an emerging anti-cancer strategy. Results Metagenomic 16S analysis was employed to explore the effect of Dichloroacetate (DCA) on the composition of the fecal microbiota and metabolomic profile was assessed on in vivo pancreatic cancer mouse xenograft model. Pancreatic cancer xenograft mice displayed a shift of microbiota’ profile as compared to control mice without DCA treatment and a significant decrease of the purine bases inosine xanthine together with their metabolically-related compound hypoxanthine were observed in the DCA treated group as compared to the control group. Two aminoacids methionine and aspartic acid resulted decreased and increased respectively. DCA affects tumor environment and studies are needed in order to understand whether DCA supplementation could be supportive as synergistic approach to enhance the efficacy of existing cancer treatments in pancreatic cancer patients.

show abstract

Section: Discussionsupporting

confidence: 80%

Inhibition of pyruvate dehydrogenase kinase influence microbiota and metabolomic profile in pancreatic cancer xenograft mice

Adamberg

Vilu

Pazienza³

2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Less pronounced but signi cant increase was also observed in bacteria belonging to Anaerotruncus (5 and 2 %, respectively) ( Figure 1B). All these changes mentioned above were conversely observed in case of gemcitabine treatment as published previously [12]. The only bacteria observed only in control group were genus Coprococcus 1 although this was low abundant genus (0.3%).…”

Section: Effect Of Dca On Microbiota Pro Le Of Pc Xenograft Micesupporting

confidence: 86%

Inhibition of pyruvate dehydrogenase kinase influence microbiota and metabolomic profile in pancreatic cancer xenograft mice

Adamberg

Vilu

Pazienza³

2020

Preprint

Self Cite

View full text Add to dashboard Cite

Objective: Despite recent advances in treatment options, pancreatic cancer remains the most deadly major cancer. Targeting metabolism represents an emerging anti-cancer strategy. Results: Metagenomic 16S analysis was employed to explore the effect of Dichloroacetate (DCA) on the composition of the fecal microbiota and metabolomic profile was assessed on in vivo pancreatic cancer mouse xenograft model. Pancreatic cancer xenograft mice displayed a shift of microbiota’ profile as compared to control mice without DCA treatment and a significant decrease of the purine bases inosine xanthine together with their metabolically-related compound hypoxanthine were observed in the DCA treated group as compared to the control group. Two aminoacids methionine and aspartic acid resulted decreased and increased respectively. DCA affects tumor environment and studies are needed in order to understand whether DCA supplementation could be supportive as synergistic approach to enhance the efficacy of existing cancer treatments in pancreatic cancer patients.

show abstract

“…3). Interestingly, the microbial dysbiosis may contribute to both cancer pathogenesis and progression [13,40]. In fact, several inflammatory factors such as pro-inflammatory cytokines and chemokines, reactive oxygen and nitrogen species, are associated to growth and spread of the cancer (Fig.…”

Section: Introductionmentioning

confidence: 99%

From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?

Mantovani

Dicitore

Barrea

et al. 2020

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Gut microbiota is represented by different microorganisms that colonize the intestinal tract, mostly the large intestine, such as bacteria, fungi, archaea and viruses. The gut microbial balance has a key role in several functions. It modulates the host’s metabolism, maintains the gut barrier integrity, participates in the xenobiotics and drug metabolism, and acts as protection against gastro-intestinal pathogens through the host’s immune system modulation. The impaired gut microbiota, called dysbiosis, may be the result of an imbalance in this equilibrium and is linked with different diseases, including cancer. While most of the studies have focused on the association between microbiota and gastrointestinal adenocarcinomas, very little is known about gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs). In this review, we provide an overview concerning the complex interplay between gut microbiota and GEP NENs, focusing on the potential role in tumorigenesis and progression in these tumors.

show abstract

Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice

Abstract: Understanding chemotherapy side effects may explain the lack of activity or the chemoresistant processes and it may help to set up strategies to improve the effectiveness of therapy.

Cited by 78 publications

References 61 publications

Inhibition of pyruvate dehydrogenase kinase influence microbiota and metabolomic profile in pancreatic cancer xenograft mice

Inhibition of pyruvate dehydrogenase kinase influence microbiota and metabolomic profile in pancreatic cancer xenograft mice

Inhibition of pyruvate dehydrogenase kinase influence microbiota and metabolomic profile in pancreatic cancer xenograft mice

From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?

Contact Info

Product

Resources

About